Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Dec 31;20(1):2350815.
doi: 10.1080/21645515.2024.2350815. Epub 2024 May 17.

COVID-19 vaccine acceptance and its association with knowledge and attitude among patients with chronic diseases in Ethiopia

Tilahun Degu Tsega  1 , Abebaw Molla Kebede  1 , Tadesse Miretie Dessie  1 , Bezawit Adane  1 , Melaku Yalew  1 , Ahmed Fentaw Ahmed  1 , Molla Getie Mehari  2 , Gashaw Melkie Bayeh  3 , Almaw Genet Yeshiwas  3 , Mekuanent Asmare Yizengaw  4 , Tamiru Alene  5 , Zewdu Bishaw Aynalem  6
Affiliations
Meta-Analysis

COVID-19 vaccine acceptance and its association with knowledge and attitude among patients with chronic diseases in Ethiopia

Tilahun Degu Tsega et al. Hum Vaccin Immunother. .

Abstract

COVID-19 vaccine acceptance is crucial for patients with chronic diseases, but previous studies in Ethiopia have yielded inconsistent and inconclusive findings. To fill this gap, we conducted a systematic review and meta-analysis following established guidelines. Our search included relevant articles published between 2019 and 2023 from various sources. We assessed study heterogeneity and publication bias, and performed subgroup and sensitivity analyses. Our findings indicate that the COVID-19 vaccine acceptance rate among patients with chronic diseases in Ethiopia was 55.4%. We also found that good knowledge and a favorable attitude toward the vaccine were positively associated with the acceptance rate. Based on these results, we recommend that healthcare professionals, policymakers, and healthcare guide developers should work more to address the relatively low acceptance rate. Improving the knowledge and attitude further about the COVID-19 vaccines is crucial. Future research should include community-based and qualitative studies to enhance our understanding of vaccines acceptance.

Keywords: COVID-19 vaccine acceptance; Ethiopia; attitude; knowledge; patients with chronic diseases.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
PRISMA flow diagram of the included studies in the systematic review and meta-analysis of the COVID-19 vaccine acceptance and its association with knowledge and attitude among patients with chronic diseases in Ethiopia from 2019 to 2023.
Figure 2.
Figure 2.
Galbraith plot for the studies included in the systematic review and meta-analysis on the COVID-19 vaccine acceptance and its association with knowledge and attitude among patients with chronic diseases in Ethiopia.
Figure 3.
Figure 3.
Pooled magnitude of the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia from 2019 to 2023.
Figure 4.
Figure 4.
Subgroup analysis by region for the pooled magnitude of the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia.
Figure 5.
Figure 5.
Subgroup analysis by study year for the pooled magnitude of the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia.
Figure 6.
Figure 6.
Subgroup analysis by publication status for the pooled magnitude of the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia.
Figure 7.
Figure 7.
Subgroup analysis by study’s sample size for the pooled magnitude of the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia.
Figure 8.
Figure 8.
Subgroup analysis by level of response rate for the pooled magnitude of the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia.
Figure 9.
Figure 9.
Subgroup analysis by level of study’s quality for the pooled magnitude of the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia.
Figure 10.
Figure 10.
Sensitivity analysis for the pooled magnitude of the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia.
Figure 11.
Figure 11.
Funnel plot showing publication bias for the pooled magnitude of the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia.
Figure 12.
Figure 12.
Funnel plot after trim and fill analysis for the pooled magnitude of the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia.
Figure 13.
Figure 13.
Forest plot of the effect of knowledge on the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia.
Figure 14.
Figure 14.
Subgroup analysis by study year for the effect of knowledge on the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia.
Figure 15.
Figure 15.
Subgroup analysis by publication status for the effect of knowledge on the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia.
Figure 16.
Figure 16.
Subgroup analysis by sample size for the effect of knowledge on the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia.
Figure 17.
Figure 17.
Subgroup analysis by quality status for the effect of knowledge on the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia.
Figure 18.
Figure 18.
Funnel plot for the effect of knowledge on the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia.
Figure 19.
Figure 19.
Sensitivity analysis for the effect of knowledge on the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia.
Figure 20.
Figure 20.
Forest plot for the pooled effect of attitude toward the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia.
Figure 21.
Figure 21.
Subgroup analysis by publication status for the effect of attitude on the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia.
Figure 22.
Figure 22.
Subgroup analysis by sample size for the effect of attitude on the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia.
Figure 23.
Figure 23.
Sensitivity analysis of the effect of attitude toward the COVID-19 vaccine acceptance among patients with chronic diseases in Ethiopia.
See this image and copyright information in PMC

References

    1. Poukka E, Nohynek H, Goebeler S, Leino T, UJm B.. Bivalent booster effectiveness against severe COVID-19 outcomes in Finland, September 2022–March 2023. medRxiv. 2023;2023.03. 02.23286561. - PMC - PubMed
    1. Nehal KR, Steendam LM, Campos Ponce M, van der Hoeven M, Smit GSA. Worldwide vaccination willingness for COVID-19: a systematic review and meta-analysis. Vaccines. 2021;9(10):1071. doi: 10.3390/vaccines9101071. - DOI - PMC - PubMed
    1. Hacker KA, Briss PA, Richardson L, Wright J, Petersen R. Peer reviewed: COVID-19 and chronic disease: the impact now and in the future. Prev Chronic Dis. 2021;18. doi: 10.5888/pcd18.210086. - DOI - PMC - PubMed
    1. Montarello NL, Wong HZ, Jeffries A, Perkins GB, Hissaria P, Stokes MB, Raith E, Teo K, Bradley J. Pfizer BNT 162b2 COVID-19 vaccine–induced fulminant myopericarditis: a case study. Crit Care Resusc. 2023;25(3):155–20. doi: 10.1016/j.ccrj.2023.06.005. - DOI - PMC - PubMed
    1. Hussain A, Bhowmik B, Do Vale Moreira NC. COVID-19 and diabetes: knowledge in progress. Diabetes Res Clin Pract. 2020;162:108142. doi: 10.1016/j.diabres.2020.108142. - DOI - PMC - PubMed

MeSH terms